Omega Therapeutics, Inc. financial data

Symbol
OMGA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
140 First Street, Suite 501, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 307 % -52.6%
Debt-to-equity 284 % +436%
Return On Equity -156 % -60.8%
Return On Assets -40.8 % +35.9%
Operating Margin -1.28K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55.2M shares +0.03%
Common Stock, Shares, Outstanding 55.2M shares +0.03%
Entity Public Float 140M USD +75.3%
Common Stock, Value, Issued 55K USD 0%
Weighted Average Number of Shares Outstanding, Basic 55.2M shares +0.14%
Weighted Average Number of Shares Outstanding, Diluted 55.2M shares +0.14%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 6.31M USD +181%
Research and Development Expense 60.4M USD -34.9%
General and Administrative Expense 26.6M USD +6.81%
Operating Income (Loss) -80.6M USD +29%
Nonoperating Income (Expense) 1.74M USD -14%
Net Income (Loss) Attributable to Parent -78.9M USD +29.3%
Earnings Per Share, Basic -1.42 USD/shares +36%
Earnings Per Share, Diluted -1.42 USD/shares +36%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 45.9M USD -56.6%
Marketable Securities, Current 4.99M USD -90.8%
Assets, Current 56.1M USD -55.1%
Property, Plant and Equipment, Net 4.92M USD -11%
Operating Lease, Right-of-Use Asset 107M USD +9.3%
Other Assets, Noncurrent 51K USD -66%
Assets 168M USD -26.5%
Accounts Payable, Current 1.72M USD -72.8%
Employee-related Liabilities, Current 2.08M USD -21%
Accrued Liabilities, Current 3.94M USD -45.3%
Liabilities, Current 25.5M USD -24.1%
Operating Lease, Liability, Noncurrent 98.2M USD +12.3%
Other Liabilities, Noncurrent 5.3M USD +1459%
Liabilities 142M USD +6.66%
Accumulated Other Comprehensive Income (Loss), Net of Tax -14K USD +97.1%
Retained Earnings (Accumulated Deficit) -371M USD -27%
Stockholders' Equity Attributable to Parent 26.3M USD -72.6%
Liabilities and Equity 168M USD -26.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.8M USD +58%
Net Cash Provided by (Used in) Financing Activities -1.07M USD -103%
Net Cash Provided by (Used in) Investing Activities 4.47M USD -79.8%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 55.2M shares +0.03%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.41M USD -125%
Interest Paid, Excluding Capitalized Interest, Operating Activities 484K USD +25.1%
Deferred Tax Assets, Valuation Allowance 105M USD +41.4%
Deferred Tax Assets, Gross 134M USD +78.7%
Operating Lease, Liability 110M USD +11.5%
Depreciation 1.84M USD +26.1%
Payments to Acquire Property, Plant, and Equipment 535K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -78.7M USD +28.9%
Lessee, Operating Lease, Liability, to be Paid 197M USD +7.8%
Property, Plant and Equipment, Gross 11.9M USD +6.31%
Operating Lease, Liability, Current 11.8M USD +5.77%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.4M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 12.1M USD +5.99%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 87.1M USD +3.44%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.7M USD
Deferred Tax Assets, Operating Loss Carryforwards 50.8M USD +26.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 13.1M USD
Operating Lease, Payments 2.34M USD +511%
Additional Paid in Capital 397M USD +2.34%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 29.7M USD +2387%
Share-based Payment Arrangement, Expense 9.04M USD +6.38%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%